BR112023017763A2 - Inibidores kras g12d - Google Patents

Inibidores kras g12d

Info

Publication number
BR112023017763A2
BR112023017763A2 BR112023017763A BR112023017763A BR112023017763A2 BR 112023017763 A2 BR112023017763 A2 BR 112023017763A2 BR 112023017763 A BR112023017763 A BR 112023017763A BR 112023017763 A BR112023017763 A BR 112023017763A BR 112023017763 A2 BR112023017763 A2 BR 112023017763A2
Authority
BR
Brazil
Prior art keywords
kras
inhibitors
compounds
methods
relates
Prior art date
Application number
BR112023017763A
Other languages
English (en)
Inventor
Edward Fink Brian
Hasibur Rahaman
Khehyong Ngu
Lan-Ying Qin
S Shirude Pravin
Joseph Cherney Robert
Upender Velaparthi
David Vaccaro Wayne
Zheming Ruan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112023017763A2 publication Critical patent/BR112023017763A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

inibidores kras g12d. a presente invenção refere-se a inibidores de kras. também são fornecidos métodos de tratamento de cânceres utilizando os compostos.
BR112023017763A 2021-03-12 2022-03-14 Inibidores kras g12d BR112023017763A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163160431P 2021-03-12 2021-03-12
US202163173021P 2021-04-09 2021-04-09
US202163220386P 2021-07-09 2021-07-09
US202163236497P 2021-08-24 2021-08-24
PCT/US2022/020239 WO2022192794A1 (en) 2021-03-12 2022-03-14 Kras g12d inhibitors

Publications (1)

Publication Number Publication Date
BR112023017763A2 true BR112023017763A2 (pt) 2023-10-03

Family

ID=81213567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017763A BR112023017763A2 (pt) 2021-03-12 2022-03-14 Inibidores kras g12d

Country Status (9)

Country Link
EP (1) EP4305038A1 (pt)
JP (1) JP2024510606A (pt)
KR (1) KR20230169967A (pt)
AU (1) AU2022232523A1 (pt)
BR (1) BR112023017763A2 (pt)
CA (1) CA3210053A1 (pt)
IL (1) IL305568A (pt)
MX (1) MX2023010430A (pt)
WO (1) WO2022192794A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115181106B (zh) * 2021-04-07 2024-04-05 药雅科技(上海)有限公司 喹唑啉类krasg12d突变蛋白抑制剂的制备及其应用
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
EP4371991A1 (en) * 2022-01-21 2024-05-22 Usynova Pharmaceuticals Ltd. Benzopyrimidine compounds and use thereof
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
WO2024067714A1 (zh) * 2022-09-30 2024-04-04 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用
WO2024092420A1 (zh) * 2022-10-31 2024-05-10 上海皓元医药股份有限公司 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
CA3063440A1 (en) * 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
WO2021031952A1 (zh) * 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途

Also Published As

Publication number Publication date
IL305568A (en) 2023-10-01
AU2022232523A1 (en) 2023-11-16
CA3210053A1 (en) 2022-09-15
KR20230169967A (ko) 2023-12-18
EP4305038A1 (en) 2024-01-17
MX2023010430A (es) 2023-09-12
JP2024510606A (ja) 2024-03-08
WO2022192794A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
BR112023017763A2 (pt) Inibidores kras g12d
BR112023017661A2 (pt) Inibidores de kras
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
CL2022001731A1 (es) Inhibidores de egfr.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201991198A1 (ru) АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CY1120826T1 (el) Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης
UA107796C2 (en) Tetracyclic compound
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
BR112022001291A2 (pt) Amidas heterobicíclicas como inibidores de cd38
BR112021024236A2 (pt) Proteínas multiespecíficas
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201792287A1 (ru) Способы лечения рака
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
CY1124565T1 (el) Αναστολεις πολυμερασης πολυ-adp ριβοζης (parp)